NULL
Immunovaccine (IMMVF) Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF) today announced that the first patient has been treated in a Phase 2 Study combining DPX-Survivac with Low Dose Cyclophosphamide
- 1 min Read
- 03.28.2018
-
Stocks Mentioned
in this Article
A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.
Of course, I couldn’t envision the extent to which AI would take off when I initially urged you to buy Nvidia.
Vulnerability depends on factors such as energy self-sufficiency, alternative energy adoption and economic resilience.
They're now able to use AI to assess data generated by everything from drills and trucks to conveyors and ships.
Trucking is one of the purest forms of economic supply and demand out there.
The upgrade is a watershed moment for Mexican airlines, allowing carriers to add new U.S. routes.
